Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Sklavenitis-Pistofidis R, et al. Among authors: lightbody ed. Cancer Cell. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017. Cancer Cell. 2022. PMID: 36379208 Free PMC article.
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.
Dutta AK, Alberge JB, Lightbody ED, Boehner CJ, Dunford A, Sklavenitis-Pistofidis R, Mouhieddine TH, Cowan AN, Su NK, Horowitz EM, Barr H, Hevenor L, Beckwith JB, Perry J, Cao A, Lin Z, Kuhr FK, Mastro RGD, Nadeem O, Greipp PT, Stewart C, Auclair D, Getz G, Ghobrial IM. Dutta AK, et al. Among authors: lightbody ed. Cancer Discov. 2023 Feb 6;13(2):348-363. doi: 10.1158/2159-8290.CD-22-0482. Cancer Discov. 2023. PMID: 36477267
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecká V, Pospíšilová L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hájek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Cowan A, et al. Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6. Lancet Haematol. 2023. PMID: 36858677 Free PMC article.
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson K, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM. Nadeem O, et al. Among authors: lightbody ed. medRxiv [Preprint]. 2024 Apr 19:2024.04.19.24306082. doi: 10.1101/2024.04.19.24306082. medRxiv. 2024. PMID: 38699307 Free PMC article. Preprint.
Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.
Tahri S, Piccinelli S, Su NK, Lampe L, Dong H, Vergara Cadavid J, Boiarsky R, Papazian N, Lightbody ED, Cao A, Alberge JB, Ferrari de Andrade L, Rahmat M, Shen Y, Blanco Fernández L, Zabaleta A, Günther A, Getz G, Sonneveld P, Cupedo T, Wucherpfennig KW, Ghobrial IM, Romee R. Tahri S, et al. Among authors: lightbody ed. Blood Adv. 2024 Oct 22;8(20):5365-5370. doi: 10.1182/bloodadvances.2023010869. Blood Adv. 2024. PMID: 39106432 Free PMC article. No abstract available.
Serum free light chains in a racially diverse population including African Americans and populations from South Africa.
Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, Murphy CSM, Colchie J, Davis MI, Perry J, Lightbody ED, Allam S, Goqwana LN, Philip V, Smyth NA NA, Sakrikar D, Perkins MC, Harding S, Troske D, Getz G, Karlson EW, Munshi NC, Anderson KC, Trippa L, Marinac CR, Chen WC, Joffe M, Ghobrial IM. Bertamini L, et al. Among authors: lightbody ed. Blood. 2024 Nov 21:blood.2024026078. doi: 10.1182/blood.2024026078. Online ahead of print. Blood. 2024. PMID: 39571144
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson KC, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM. Nadeem O, et al. Among authors: lightbody ed. Nat Commun. 2025 Jan 3;16(1):358. doi: 10.1038/s41467-024-55308-5. Nat Commun. 2025. PMID: 39753553 Free PMC article. Clinical Trial.
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.
Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Aranha MP, Heilpern-Mallory D, Huynh D, Chong SJF, Hackett L, Haradhvala NJ, Wu T, Su NK, Berrios B, Alberge JB, Dutta A, Davids MS, Papaioannou M, Getz G, Ghobrial IM, Manier S. Sklavenitis-Pistofidis R, et al. Among authors: lightbody ed. bioRxiv [Preprint]. 2023 Aug 3:2023.08.01.551480. doi: 10.1101/2023.08.01.551480. bioRxiv. 2023. PMID: 37577538 Free PMC article. Preprint.
Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N, Li D, Conseil G, Lightbody ED, Wilson-Sanchez J, Hamade A, Chenard S, Jawa NA, Laight BJ, Afriyie-Asante A, Tyryshkin K, Koebel M, Koti M. Shakfa N, et al. Among authors: lightbody ed. J Immunother Cancer. 2023 Apr;11(4):e006170. doi: 10.1136/jitc-2022-006170. J Immunother Cancer. 2023. PMID: 37015760 Free PMC article.
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. El-Khoury H, et al. Among authors: lightbody ed. Lancet Haematol. 2022 May;9(5):e340-e349. doi: 10.1016/S2352-3026(22)00069-2. Epub 2022 Mar 25. Lancet Haematol. 2022. PMID: 35344689 Free PMC article.
18 results